Cardiovascular morbidity and mortality in surgically treated hyperthyroidism - a nation-wide cohort study with a

Essi Ryödi1, Jorma Salmi, Pia Jaatinen

  • 1Heart Center Co., Tampere University Hospital, Tampere, Finland; School of Medicine, University of Tampere, Tampere, Finland.

Clinical Endocrinology
|December 6, 2013
PubMed

Insights

Hyperthyroidism increases cardiovascular disease hospitalization risk for up to 20 years post-thyroidectomy, but does not raise mortality. This long-term study highlights sustained cardiovascular risks in treated hyperthyroid patients.

Area of Science:

  • Endocrinology
  • Cardiology
  • Public Health

Background:

  • Hyperthyroidism is linked to increased cardiovascular morbidity, even after achieving euthyroidism.
  • Mechanisms and treatment-specific risks for cardiovascular complications in hyperthyroidism require further elucidation.
  • Long-term cardiovascular outcomes following surgical treatment for hyperthyroidism are not fully understood.

Purpose of the Study:

  • To compare cardiovascular hospitalization rates and mortality in surgically treated hyperthyroid patients versus a matched reference population.
  • To investigate the long-term cardiovascular risk trajectory following thyroidectomy for hyperthyroidism.

Main Methods:

  • A population-based cohort study involving 4334 hyperthyroid patients treated with thyroidectomy (1986-2007) and 12,991 controls.
  • Analysis of cardiovascular disease (CVD) hospitalizations prior to thyroidectomy.
  • Cox regression analysis to determine hazard ratios for post-thyroidectomy CVD hospitalizations, adjusted for prevalent CVD.

Main Results:

  • Cardiovascular disease hospitalization risk was 50% higher in hyperthyroid patients 5 years before thyroidectomy (P < 0.001).
  • Post-thyroidectomy, hospitalizations for all CVDs (HR 1.15), hypertension (HR 1.23), heart failure (HR 1.17), and valvular diseases/cardiomyopathies (HR 1.55) remained elevated for two decades.
  • No significant difference in cardiovascular mortality was observed between hyperthyroid patients and controls.

Conclusions:

  • Hyperthyroidism significantly elevates the risk of cardiovascular disease hospitalization, a risk that persists for up to 20 years after thyroidectomy.
  • Effective surgical treatment for hyperthyroidism does not eliminate the long-term increased risk of cardiovascular hospitalizations.
  • Despite increased cardiovascular morbidity, excess cardiovascular mortality was not found in this middle-aged cohort.
Abstract

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
28
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
26
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K